1. Home
  2. ROC vs CING Comparison

ROC vs CING Comparison

Compare ROC & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rank One Computing Corporation Common stock

ROC

Rank One Computing Corporation Common stock

N/A

Current Price

$3.66

Market Cap

71.2M

Sector

N/A

ML Signal

N/A

CING

Cingulate Inc.

HOLD

Current Price

$4.66

Market Cap

70.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROC
CING
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2M
70.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
ROC
CING
Price
$3.66
$4.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$7.75
★ $21.20
AVG Volume (30 Days)
25.4K
★ 90.8K
Earning Date
08-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
★ $16,979,679.00
N/A
Revenue This Year
$21.30
N/A
Revenue Next Year
$72.97
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 23.90
N/A
52 Week Low
$3.35
$3.16
52 Week High
$7.80
$11.89

Technical Indicators

Market Signals
Indicator
ROC
CING
Relative Strength Index (RSI) 43.78 44.48
Support Level $3.63 $4.19
Resistance Level $4.59 $5.20
Average True Range (ATR) 0.28 0.24
MACD -0.01 0.01
Stochastic Oscillator 46.57 60.81

Price Performance

Historical Comparison
ROC
CING

About ROC Rank One Computing Corporation Common stock

Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: